SCHEMBL7036281

SCHEMBL7036281

CCOC(=O)c1sc(Oc2cccnc2)c2c1CCc1cnn(C)c1-2

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCNC P24863 10/20 0.59
CDK8 P49336 10/20 0.59
CDK19 Q9BWU1 10/20 0.59
DRD2 P14416 1/20 0.41
DRD4 P21917 1/20 0.41
CDK4 P11802 1/20 0.39
CCNA2 P20248 1/20 0.39
CDK2 P24941 1/20 0.39
CCND3 P30281 1/20 0.39
CCNA1 P78396 1/20 0.39
CDK6 Q00534 1/20 0.39
KDM4E B2RXH2 3/20 0.38
MAPT P10636 3/20 0.38
ALDH1A1 P00352 3/20 0.38
PKM P14618 2/20 0.38
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
LMNA P02545 1/20 0.38
CDC7 O00311 2/20 0.38
DBF4 Q9UBU7 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7242256 0.91 CCNC (0.58) CCNCCDK8CDK19DRD2DRD4
Hydrochloric Acid SCHEMBL7094343 0.88 CCNC (0.57) CCNCCDK8CDK19DRD2DRD4
SCHEMBL7038809 0.88 CCNC (0.61) CCNCCDK8CDK19DRD2DRD4
SCHEMBL7242865 0.87 CCNC (0.54) CCNCCDK8CDK19DRD2DRD4
SCHEMBL7040422 0.87 CCNC (0.73) CCNCCDK8CDK19
SCHEMBL7249230 0.87 CCNC (0.55) CCNCCDK8CDK19DRD2DRD4
SCHEMBL15104759 0.86 CCNC (0.79) CCNCCDK8CDK19DRD2DRD4
SCHEMBL7038710 0.86 CCNC (0.54) CCNCCDK8CDK19DRD2DRD4
SCHEMBL7243143 0.86 CCNC (0.61) CCNCCDK8CDK19DRD2DRD4
SCHEMBL7242242 0.86 CCNC (0.45) CCNCCDK8CDK19CDK4CCNA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030185878-A1 Process for producing phospholipid-containing drug TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2003-10-02 US disclosed
EP-1293197-A1 PROCESS FOR PRODUCING PHOSPHOLIPID-CONTAINING DRUGS Takeda Chemical Industries, Ltd. (JP) 2003-03-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030185878-A1 Process for producing phospholipid-containing drug PHOSPHO1, PLTP, PTDSS2 CCNC 3385/4885CDK8 2673/4885CDK19 3344/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.